Bahler Clinton D, Maniar Viraj, Marley Kristen N, Kheyfets Steven V, Shum Cheuk Fan, Sundaram Chandru P
Department of Urology, Indiana University School of Medicine, Indianapolis, Indiana.
J Endourol B Videourol. 2017 Feb 6;31(3). doi: 10.1089/vid.2016.0068. eCollection 2017.
The folate receptor (FR) protein is upregulated in numerous epithelial malignancies while having limited expression on normal tissues. This overexpression of FR in renal-cell carcinoma (RCC) can be exploited by attaching nearly any therapeutic or imaging agent for delivery to cancer cells. In one of its first applications, platinum-resistant ovarian cancer, folate was used to deliver pegylated liposomal doxorubicin (a folate-linked vinca alkaloid) and improved progression-free survival versus standard treatment. RCCs are thought to be the second highest FR-expressing cancer. OTL-38 is a folate analogue conjugated with a fluorescent dye that emits light in the near infrared spectrum. This longer wavelength allows for deeper penetration of the fluorescent light through tissues with the potential to better image tumors beneath adipose tissue or deeper into organ parenchyma. We are currently conducting a pilot, phase 2, nonrandomized study in patients with RCC, scheduled to undergo primary, partial, or radical nephrectomy. The aim is to explore the use of OTL-38 and fluorescence imaging to observe RCC at the margins of resection in partial nephrectomy and in lymph node(s) or other metastases for radical nephrectomy. Currently two patients have participated in the trial to date with an accrual target of 20 patients. The first was a 67-year-old male with an incidental 2.2 cm right-sided renal mass, and the second was a 70-year-old male with an enlarging 2 cm renal mass. Per protocol, both patients were administered OTL-38 in the preoperative area 1 hour before the procedure. Subsequently, both procedures were performed with robotic assistance as per normal routine with the use of Firefly fluorescence to aid in observation of OTL-38 uptake. Intraoperative guidance through OTL-38 demonstrated minimal to no uptake of the OTL-38 as seen by Firefly fluorescence (green color). Surprisingly, the normal renal parenchyma showed strong uptake of OTL-38 as seen by Firefly fluorescence. Both pathology reports revealed conventional clear cell RCC. Immunohistochemistry slides of the tumor revealed only mild staining for folate. In contrast, immunohistochemistry slides of the normal renal parenchyma in the surgical margin revealed a strongly positive stain for folate. In conclusion, our first two patients' renal tumors did not stain strongly for folate; however, the normal renal parenchyma did, which served as an intraoperative guide to confirm a negative margin. Further study of patients will reveal whether folate receptors are, in fact, predominant or not in renal cell cancer. No competing financial interests exist. Runtime of video: 5 mins Presented at the World Congress of Endourology 2016 in Capetown, South Africa.
叶酸受体(FR)蛋白在众多上皮性恶性肿瘤中上调,而在正常组织中表达有限。肾细胞癌(RCC)中FR的这种过表达可通过连接几乎任何治疗或成像剂来输送到癌细胞而加以利用。在其最初的应用之一——铂耐药卵巢癌中,叶酸被用于递送聚乙二醇化脂质体阿霉素(一种叶酸连接的长春花生物碱),与标准治疗相比,可改善无进展生存期。肾细胞癌被认为是FR表达第二高的癌症。OTL-38是一种与荧光染料偶联的叶酸类似物,能在近红外光谱中发光。这种较长的波长使荧光能更深地穿透组织,有可能更好地对脂肪组织下方或器官实质更深层的肿瘤进行成像。我们目前正在对计划接受一期、部分或根治性肾切除术的肾细胞癌患者进行一项2期非随机试点研究。目的是探索使用OTL-38和荧光成像来观察部分肾切除术中切除边缘的肾细胞癌以及根治性肾切除术中淋巴结或其他转移灶中的肾细胞癌。到目前为止,已有两名患者参与了该试验,计划招募20名患者。第一名是一名67岁男性,偶然发现右侧肾脏有一个2.2厘米的肿块,第二名是一名70岁男性,其2厘米的肾脏肿块在增大。按照方案,两名患者在手术前1小时在术前区域接受了OTL-38给药。随后,按照常规,在Firefly荧光的辅助下,两台手术均在机器人辅助下进行,以帮助观察OTL-38的摄取情况。通过OTL-38进行的术中引导显示,Firefly荧光(绿色)显示OTL-38的摄取极少或无摄取。令人惊讶的是,正常肾实质在Firefly荧光下显示出强烈的OTL-38摄取。两份病理报告均显示为传统的透明细胞肾细胞癌。肿瘤的免疫组织化学切片显示叶酸染色仅为轻度。相比之下,手术边缘正常肾实质的免疫组织化学切片显示叶酸染色呈强阳性。总之,我们的前两名患者的肾肿瘤叶酸染色不强;然而,正常肾实质的叶酸染色强,这在术中可作为确认切缘阴性的指导。对更多患者的进一步研究将揭示叶酸受体在肾细胞癌中是否真的占主导地位。不存在相互竞争的经济利益。视频时长:5分钟。于2016年在南非开普敦举行的世界腔内泌尿外科大会上发表。